Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Regenerative medicine company, Avita Medical (ASX: AVH), will enter into a preclinical trial collaboration with the Gates Center for Regenerative Medicine
  • The collaboration will explore the potential of a spray-on treatment of genetically modified cells for epidermolysis bullosa
  • This group of rare genetic disorders causes the skin to blister easily and can result in chronic wounds or even death
  • Shares in the company are up, trading for 57.5 cents at market close

Avita Medical will enter into a preclinical trial collaboration with the Gates Centre for Regenerative Medicine.

The Sponsored Research Agreement (SRA) with the Gates Center will explore the potential of a spray-on treatment of genetically modified cells for patients with epidermolysis bullosa, a group of rare genetic disorders.

The disease is caused by a gene mutations and results in severe blistering of the skin. The degree of severity varies between patients but can lead to chronic wounds or even death.

On the other hand, Avita Medical is a regenerative medicine company that specialises in skin, burns and chronic wounds. The company’s exisiting products use the patients’ skin to make a spray-on-skin cell technology.

Currently there are about half a million people affected by epidermolysis bullosa, with the current treatment relying on hard-to-grow skin grafts.

The Gates Center is optimistic about the possible outcome for patients from the collaboration, according to co-principal investigator of the epidermolysis bullosa program, Dr Ganna Bilousova.

“We believe that Spray-On SkinTM Cells technology combined with our genetically corrected cells has the potential to be game changing in the treatment of this disease. This combination could reduce time to treatment, lower manufacturing complexity, reduce costs and improve patient outcomes,” she said.

Under the terms of the SRA, Avita Medical will retain the right to exclusively licence technologies emerging from the partnership.

Avita Medical shares were up after the news, trading for 57.5 cents each at market close.

AVH by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.